查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1500092

基因組學市場中的人工智慧 - 全球行業規模、佔有率、趨勢、機會和預測，按組件、技術、功能、應用、最終用途、地區和競爭細分，2019-2029F

AI In Genomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Technology, By Functionality, By Application, By End Use, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球基因組學人工智慧市場估值為4.7921 億美元，預計到2029 年，預測期內將穩定成長，複合年成長率為9.72%。了市場的廣泛關注。這種協同作用為理解、診斷和治療複雜的遺傳性疾病以及推動個人化醫療開闢了新途徑。基因組學市場中的人工智慧正在快速成長，有望重塑醫療保健格局。基因組學是對個體遺傳物質的研究，是深入了解疾病和疾病遺傳基礎的關鍵。然而，基因組資料的複雜性和龐大性為分析和解釋帶來了巨大的挑戰。這就是人工智慧介入的地方，它提供了一種解決方案，可以有效地處理這些複雜的資訊並從中提取有意義的見解。人工智慧演算法擅長處理大型資料集，使其成為基因組領域的完美匹配。透過應用機器學習技術，人工智慧可以識別基因組內可能被忽視的模式、相關性和異常。這使得研究人員和臨床醫生能夠找出與疾病相關的遺傳變異，為更準確的診斷和有針對性的治療鋪路。

市場概況
預測期 2025-2029
2023 年市場規模 4.7921億美元
2029 年市場規模 83252萬美元
2024-2029 年複合年成長率 9.72%
成長最快的細分市場 機器學習
最大的市場 北美洲

主要市場促進因素

基因組數據的指數成長

加速藥物發現與開發

個人化醫療和標靶治療

主要市場挑戰

數據品質和數量

可解釋和可解釋的人工智慧

道德考慮和隱私問題

主要市場趨勢

基因組數據分析與解釋

人工智慧驅動的診斷

細分市場洞察

技術洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：基因組學領域的全球人工智慧市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按組件（硬體、軟體、服務）
    • 按技術（機器學習{深度學習、監督學習、無監督學習、其他}、電腦視覺）
    • 按功能（基因組定序、基因編輯、其他）
    • 按應用（藥物發現與開發、精準醫學、診斷、其他）
    • 依最終用途（製藥和生物技術公司、醫療保健提供者、研究中心等）
    • 按公司分類 (2023)
    • 按地區
  • 市場地圖

第 6 章：北美基因組學人工智慧市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按組件
    • 依技術
    • 按功能分類
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲人工智慧在基因組學市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按組件
    • 依技術
    • 按功能分類
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區人工智慧在基因組學市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按組件
    • 依技術
    • 按功能分類
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲基因體學中的人工智慧市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按組件
    • 依技術
    • 按功能分類
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲基因組學中的人工智慧市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按組件
    • 依技術
    • 按功能分類
    • 按申請
    • 按最終用途
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • IBM Corp.
  • Deep Genomics Inc.
  • Nvidia Corporation
  • Data4Cure, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Sophia Genetics SA
  • Freenome Holdings, Inc.
  • BenevolentAI Ltd.
  • Genentech, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 23959

Global AI In Genomics Market was valued at USD 479.21 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 9.72% through 2029. In recent years, the convergence of artificial intelligence (AI) and genomics has ignited a transformative revolution in the healthcare industry. This synergy has opened up new avenues for understanding, diagnosing, and treating complex genetic disorders, as well as advancing personalized medicine. The AI in genomics market is witnessing rapid growth, poised to reshape the landscape of healthcare. Genomics, the study of an individual's genetic material, holds the key to unlocking a deeper understanding of the genetic basis of diseases and conditions. However, the complexity and vastness of genomic data pose significant challenges for analysis and interpretation. This is where artificial intelligence steps in, offering a solution to efficiently process and extract meaningful insights from this intricate information. AI algorithms excel in handling large datasets, making them a perfect match for the genomic field. By applying machine learning techniques, AI can identify patterns, correlations, and anomalies within genomes that might otherwise go unnoticed. This enables researchers and clinicians to pinpoint genetic variations associated with diseases, paving the way for more accurate diagnostics and targeted treatments.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 479.21 Million
Market Size 2029USD 832.52 Million
CAGR 2024-20299.72%
Fastest Growing SegmentMachine Learning
Largest MarketNorth America

Key Market Drivers

Exponential Growth of Genomic Data

One of the primary drivers behind the surge in AI applications in genomics is the exponential growth of genomic data. The advent of next-generation sequencing (NGS) technologies has enabled the rapid generation of vast amounts of genetic information. This deluge of data, ranging from whole genome sequences to transcriptomic profiles, presents both a challenge and an opportunity. The burgeoning field of genomics has unveiled intricate genetic variations, mutations, and regulatory elements that underlie various diseases and biological processes. However, the sheer volume of data generated presents a unique challenge i.e, making sense of the information hidden within the vast genomic landscapes. Artificial Intelligence, particularly machine learning (ML) and deep learning, has demonstrated its prowess in handling complex and high-dimensional data. In the realm of genomics, AI algorithms can analyze, interpret, and predict biological phenomena with remarkable accuracy. The combination of AI and genomics is a natural progression, driven by the need to extract meaningful insights from the vast genomic datasets. A key area where AI has made significant strides is in the identification of disease-causing genetic mutations. In the past, identifying the genetic basis of a disease was a laborious process, often requiring years of painstaking research.

With the advent of AI, this process has been accelerated dramatically. AI algorithms can rapidly sift through vast genomic datasets to pinpoint mutations associated with specific diseases. This has not only accelerated the understanding of genetic disorders but has also paved the way for more targeted and personalized treatments. AI's ability to identify patterns, detect anomalies, and uncover correlations within genomic data is invaluable for both research and clinical applications. ML models can identify potential disease-causing mutations, predict patient outcomes, and optimize drug discovery pipelines. AI-driven tools can unravel the complexities of gene expression, protein interactions, and regulatory networks, shedding light on the underlying mechanisms of diseases. AI excels at handling large datasets, and genomics is no exception. The sheer volume and complexity of genomic data require advanced computational methods to extract meaningful insights. AI algorithms can sift through massive datasets to identify patterns, correlations, and genetic variations associated with diseases. As the volume of genomic data continues to expand, the demand for AI-driven solutions becomes increasingly crucial for making sense of this wealth of information.

Accelerating Drug Discovery and Development

The integration of AI in genomics has revolutionized the drug discovery and development process. Traditional drug development can take years and incur exorbitant costs. AI algorithms have the potential to drastically reduce both the time and financial investments required.AI-driven genomics assists researchers in identifying potential drug targets with precision. By analyzing the interactions between genes, proteins, and pathways, AI algorithms can predict the impact of genetic variations on protein structures and functions. This predictive capability allows researchers to focus their efforts on developing drugs that are more likely to succeed. Traditional drug discovery pipelines involve extensive trial-and-error experimentation, often resulting in costly failures. The vastness of chemical and biological space, coupled with the complexity of disease mechanisms, has made the process incredibly challenging. This inefficiency has driven the pharmaceutical industry to seek innovative approaches that can expedite the process without compromising on safety and efficacy. Enter artificial intelligence, a technology that is transforming industries across the board. In drug discovery and development, AI is proving to be a game-changer.

Genomics, which provides insights into the genetic underpinnings of diseases, has become a crucial ally in this AI-driven revolution. AI algorithms can analyze extensive genomic datasets to identify potential drug targets, predict compound interactions, and optimize molecular structures. AI's impact begins at the very start of the drug discovery pipeline - target identification. Through the analysis of genomic data, AI can identify genes or proteins that play a critical role in disease pathways. These insights are invaluable in pinpointing potential drug targets. The traditional hit-or-miss approach is replaced by AI's ability to predict which molecules will interact with these targets and modulate disease mechanisms. This predictive power not only expedites the process but also increases the likelihood of success. AI doesn't stop at target identification; it extends to compound design as well. By harnessing AI algorithms, researchers can predict the properties of potential drug candidates. This enables the identification of molecules that are likely to have optimal binding affinity, bioavailability, and minimal toxicity. This predictive modeling accelerates the compound optimization phase, making it more efficient and cost-effective.

Personalized Medicine and Targeted Treatments

The concept of personalized medicine, tailoring medical treatments to an individual's genetic makeup and health history, has gained significant traction with the emergence of AI in genomics. Traditional medical approaches often adopt a one-size-fits-all strategy, which can result in suboptimal outcomes and adverse reactions for some patients. AI-driven genomics is transforming this paradigm by enabling personalized treatment strategies. AI has been playing a significant role in advancing the field of precision medicine. By analyzing large-scale genomic and clinical data, AI algorithms can identify patterns and correlations that help predict disease risk, diagnose conditions earlier, and personalize treatment plans based on individual genetic profiles. Personalized medicine, once confined to the realm of science fiction, has now become a reality due to the convergence of artificial intelligence (AI) and genomics. The integration of these two cutting-edge fields is revolutionizing healthcare by tailoring medical treatments to an individual's unique genetic makeup and health history. In contrast to traditional medical approaches that often employ a one-size-fits-all strategy, personalized medicine fueled by AI in genomics holds the promise of more effective treatments, fewer adverse reactions, and improved patient outcomes. At the core of personalized medicine lies genomics - the study of an individual's unique genetic information.

Each person's DNA holds a treasure trove of insights into their susceptibility to diseases, their response to medications, and their overall health trajectory. Genomic data has the power to reveal genetic mutations that increase disease risk, genetic variations that impact drug metabolism, and genetic markers that determine treatment efficacy. However, the complexity and vastness of genomic data make its analysis a formidable challenge. This is where AI steps in as an indispensable tool, capable of processing and interpreting the intricate patterns within genetic information. AI algorithms can analyze an individual's genetic profile, along with clinical and lifestyle data, to predict disease risks and treatment responses. This information empowers healthcare providers to develop customized treatment plans that optimize patient outcomes. From selecting the most effective medications to anticipating disease progression, AI in genomics enhances the precision and effectiveness of medical interventions. AI algorithms possess the ability to sift through vast genomic datasets, identifying meaningful associations that may otherwise remain hidden. These algorithms can identify genetic mutations associated with specific diseases, predict an individual's likelihood of developing certain conditions, and even anticipate how an individual will respond to a particular treatment.

Key Market Challenges

Data Quality and Quantity

The primary focus of AI in genomics lies data - specifically, high-quality and diverse genomic datasets. The accuracy and representativeness of these datasets directly impact the performance of AI algorithms. Unfortunately, challenges related to data quality and quantity persist. Genomic data is generated through various technologies and platforms, each with its own biases and limitations. Integrating data from multiple sources and technologies can introduce noise and inconsistencies that can affect the reliability of AI predictions. The availability of diverse and well-annotated datasets is essential for training AI models that can generalize across different populations and genetic backgrounds. Addressing these challenges requires concerted efforts to curate, standardize, and share high-quality genomic datasets. Collaboration between research institutions, data repositories, and AI developers is critical to ensure that the data used to train AI models accurately reflects the complexity of the human genome.

Interpretable and Explainable AI

The "black-box" nature of some AI algorithms poses a significant challenge in the genomics field, where transparency and interpretability are paramount. In medical applications, understanding the rationale behind AI-generated insights is crucial for gaining trust from healthcare professionals, researchers, and patients. The inability to explain AI predictions can hinder the adoption of AI-driven solutions in clinical practice. Researchers and developers are actively working on developing AI models that provide interpretable outputs. Techniques such as attention mechanisms, feature visualization, and model explanations aim to shed light on how AI arrives at its conclusions. Balancing the need for interpretability with the complexity of genomic data is a delicate endeavor that requires collaboration between AI experts and domain-specific researchers.

Ethical Considerations and Privacy Concerns

AI in genomics raises important ethical and privacy considerations. Genomic data is inherently sensitive, containing information about an individual's health, ancestry, and potential predisposition to diseases. Ensuring the responsible use, storage, and sharing of this data is essential to maintain patient trust and uphold ethical standards. Data breaches, unauthorized access, and potential misuse of genomic data are real concerns. Regulatory frameworks that dictate how genomic data can be collected, shared, and used must be established to protect patient privacy and ensure ethical AI practices. Collaboration between AI developers, legal experts, and policymakers is vital to strike a balance between innovation and ethical safeguards.

Key Market Trends

Genomic Data Analysis and Interpretation

The proliferation of next-generation sequencing technologies has generated an unprecedented amount of genomic data. AI plays a critical role in analyzing and interpreting this data, extracting meaningful insights from the vast genetic information. By employing deep learning algorithms and natural language processing, AI systems can identify genetic variations, detect disease-causing mutations, and predict potential genetic disorders. This trend is pivotal in unraveling the complexities of the human genome and its implications for health. Deep learning, a subset of AI, has gained prominence for its ability to automatically learn and represent intricate patterns within data. In genomics, deep learning algorithms can identify genetic variations and mutations that might be linked to various diseases. By learning from vast datasets, these algorithms can recognize subtle relationships between genetic markers and disease susceptibility that might be elusive to conventional analytical methods.

AI-Powered Diagnostics

AI technologies are transforming the diagnostic landscape by enabling accurate and rapid identification of genetic disorders. One of the most promising applications of AI in genomics is the detection of disease-causing mutations. AI algorithms can sift through large genomic datasets to pinpoint mutations that are associated with specific diseases. This capability holds immense potential for early disease diagnosis, enabling healthcare providers to intervene before symptoms manifest. Machine learning algorithms can analyze genomic data to diagnose diseases, predict disease progression, and suggest appropriate interventions. This trend has the potential to revolutionize clinical diagnostics, providing early and precise diagnoses that empower healthcare providers to take proactive measures in managing diseases.

Segmental Insights

Technology Insights

Based on Technology, Machine Learning have emerged as the fastest growing segment in the Global AI In Genomics Market in 2023. The dominance of the machine learning segment in the AI in genomics market can be attributed to several key factors that have propelled its growth and prominence in the industry. Machine learning techniques have demonstrated exceptional capabilities in analyzing vast amounts of genomic data, extracting meaningful insights, and driving advancements in genomics research and applications. One of the primary reasons for the dominance of machine learning is its ability to handle complex datasets with high dimensionality and variability, which are inherent characteristics of genomic data. Machine learning algorithms excel at identifying patterns, correlations, and associations within genomic datasets, enabling researchers to uncover hidden biological insights and make clinically relevant discoveries.

Machine learning algorithms exhibit a high degree of adaptability and scalability, allowing them to continuously improve and refine their predictive performance as they are exposed to new data. This iterative learning process enables machine learning models to evolve and become increasingly accurate in predicting various genomic outcomes, such as disease risk, treatment response, and patient prognosis. The widespread availability of advanced computational resources and cloud computing infrastructure has facilitated the implementation and deployment of machine learning algorithms in genomics research and clinical practice. These resources enable researchers and healthcare professionals to efficiently process and analyze large-scale genomic datasets, accelerating the pace of genomic discoveries and translating them into actionable insights for patient care. The integration of machine learning techniques with other advanced technologies, such as next-generation sequencing and precision medicine, has further bolstered the dominance of the machine learning segment in the AI in genomics market. By leveraging machine learning algorithms to interpret genomic data in conjunction with clinical and phenotypic information, researchers and healthcare providers can achieve a more comprehensive understanding of the genetic basis of diseases and tailor personalized treatment strategies for patients.

Application Insights

Based on Application, Diagnostics have emerged as the dominating segment in the Global AI In Genomics Market in 2023. AI-powered algorithms can rapidly analyse intricate genomic patterns, enabling more accurate and efficient identification of genetic markers associated with various conditions. This capability not only expedites early disease diagnosis but also facilitates personalized treatment strategies, ultimately driving the prominence of the diagnostics segment within the AI in genomics domain. The dominance of the diagnostics segment in the AI in genomics market can further be attributed to several key factors that underscore its significance in driving market growth and adoption. Diagnostics play a pivotal role in leveraging AI technologies to analyze genomic data for disease detection, risk assessment, and treatment selection. AI-powered diagnostic tools offer unprecedented capabilities to process vast amounts of genomic information quickly and accurately, enabling healthcare providers to make informed decisions about patient care.

The rising prevalence of genetic disorders, chronic diseases, and cancer has fueled the demand for advanced diagnostic solutions that can accurately interpret genomic data. AI algorithms can sift through complex genetic variations and identify patterns associated with specific diseases, facilitating early detection and personalized treatment strategies. The integration of AI into diagnostic workflows has streamlined genomic testing processes, making them more efficient, cost-effective, and accessible to a broader patient population. Automated AI algorithms can analyze genomic sequences with greater speed and precision than traditional methods, reducing turnaround times and enhancing diagnostic accuracy. Advancements in AI-driven diagnostic technologies have spurred collaborations between healthcare institutions, research organizations, and technology companies to develop innovative solutions for genomics-based diagnostics. These partnerships have accelerated the translation of AI research into practical applications, driving market growth and expanding the utility of genomic data in clinical practice.

Regional Insights

Based on Region, North America have emerged as a dominating region in the Global AI In Genomics Market in 2023. The region's preeminence in AI-enabled genomics is a testament to its unparalleled blend of technological prowess, robust research infrastructure, and vibrant biotechnology ecosystem. At the core of North America's leadership lies its unparalleled concentration of cutting-edge technology and innovation hubs. The region boasts a rich tapestry of world-renowned research institutions, biopharmaceutical companies, and tech giants, collectively serving as engines of innovation in AI and genomics. These institutions form a dynamic ecosystem characterized by collaboration and knowledge exchange, fueling the rapid advancement of AI technologies in genomics research and application. North America's robust research infrastructure provides a solid foundation for pioneering AI-driven genomics initiatives. The region is home to state-of-the-art genomic sequencing facilities, high-performance computing centers, and data analytics platforms, facilitating the processing and analysis of vast genomic datasets with unprecedented speed and precision. This infrastructure enables researchers and healthcare professionals to harness the power of AI algorithms to unlock valuable insights from genomic data, driving scientific discovery and clinical innovation.

Key Market Players

IBM Corp.

Deep Genomics Inc.

Nvidia Corporation

Data4Cure, Inc.

Illumina, Inc.

Thermo Fisher Scientific Inc.

Sophia Genetics S.A.

Freenome Holdings, Inc.

BenevolentAI Ltd.

Genentech, Inc.

Report Scope:

In this report, the Global AI In Genomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

AI In Genomics Market, By Component:

    Hardware Software Services

AI In Genomics Market, By Technology:

    Machine Learning Computer Vision

AI In Genomics Market, By Functionality:

    Genome Sequencing Gene Editing Others

AI In Genomics Market, By Application:

    Drug Discovery & Development Precision Medicine Diagnostics Others

AI In Genomics Market, By End Use:

    Pharmaceutical and Biotech Companies Healthcare Providers Research Centres Others

AI In Genomics Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Asia Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
    Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI In Genomics Market.

Available Customizations:

Global AI In Genomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global AI In Genomics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Component (Hardware, Software, Services)
    • 5.2.2. By Technology (Machine Learning {Deep Learning, Supervised Learning, Unsupervised Learning, Others}, Computer Vision)
    • 5.2.3. By Functionality (Genome Sequencing, Gene Editing, Others)
    • 5.2.4. By Application (Drug Discovery & Development, Precision Medicine, Diagnostics, Others)
    • 5.2.5. By End Use (Pharmaceutical and Biotech Companies, Healthcare Providers, Research Centres, Others)
    • 5.2.6. By Company (2023)
    • 5.2.7. By Region
  • 5.3. Market Map

6. North America AI in Genomics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
    • 6.2.2. By Technology
    • 6.2.3. By Functionality
    • 6.2.4. By Application
    • 6.2.5. By End Use
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States AI In Genomics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Component
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Functionality
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End Use
    • 6.3.2. Mexico AI In Genomics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Component
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Functionality
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End Use
    • 6.3.3. Canada AI In Genomics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Component
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Functionality
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End Use

7. Europe AI In Genomics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Functionality
    • 7.2.4. By Application
    • 7.2.5. By End Use
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France AI In Genomics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Functionality
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End Use
    • 7.3.2. Germany AI In Genomics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Functionality
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End Use
    • 7.3.3. United Kingdom AI in Genomics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Functionality
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End Use
    • 7.3.4. Italy AI In Genomics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Component
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Functionality
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End Use
    • 7.3.5. Spain AI In Genomics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Component
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Functionality
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End Use

8. Asia Pacific AI In Genomics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Functionality
    • 8.2.4. By Application
    • 8.2.5. By End Use
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China AI In Genomics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Functionality
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End Use
    • 8.3.2. India AI In Genomics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Functionality
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End Use
    • 8.3.3. South Korea AI In Genomics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Functionality
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End Use
    • 8.3.4. Japan AI In Genomics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Functionality
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End Use
    • 8.3.5. Australia AI In Genomics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Functionality
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End Use

9. South America AI In Genomics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Functionality
    • 9.2.4. By Application
    • 9.2.5. By End Use
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil AI In Genomics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Functionality
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End Use
    • 9.3.2. Argentina AI In Genomics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Functionality
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End Use
    • 9.3.3. Colombia AI In Genomics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Functionality
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End Use

10. Middle East and Africa AI In Genomics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Functionality
    • 10.2.4. By Application
    • 10.2.5. By End Use
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa AI In Genomics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Functionality
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End Use
    • 10.3.2. Saudi Arabia AI In Genomics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Functionality
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End Use
    • 10.3.3. UAE AI In Genomics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Functionality
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. IBM Corp.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Deep Genomics Inc.
  • 15.3. Nvidia Corporation
  • 15.4. Data4Cure, Inc.
  • 15.5. Illumina, Inc.
  • 15.6. Thermo Fisher Scientific Inc.
  • 15.7. Sophia Genetics S.A.
  • 15.8. Freenome Holdings, Inc.
  • 15.9. BenevolentAI Ltd.
  • 15.10. Genentech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer